BPC-157: what does the evidence actually show?
BPC-157 has broad preclinical research interest, but the human evidence question remains unresolved. Here is what the evidence actually shows.
Research Hub
BPC-157
The peptide boom: what The Atlantic got right — and where the story gets more complicated
For laboratory and research use only. The Atlantic published a feature today on the underground peptide market — part of the wave of mainstream coverage that’s followed the GLP-1 boom and the broader emergence of peptide compounds in public conversation. It’s serious journalism. It deserves a serious response: one that engages with what it got […]
BPC-157 musculoskeletal research: systematic review
A systematic review examines BPC-157 in musculoskeletal research. We analyse the preclinical evidence across tendon, ligament, muscle and bone models and identify remaining gaps.
FDA peptide reclassification: what it means for research
RFK Jr. announced 14 restricted peptides returning to legal compounding. What does this FDA peptide reclassification mean for BPC-157, TB-500, and research?